AI Article Synopsis
- * This inflammation in obese individuals may worsen conditions like psoriasis and is also seen in diseases like rheumatoid arthritis and Crohn's disease.
- * There’s a noted connection between psoriasis, obesity, and increased cardiovascular issues, but further research is needed to understand the roles of obesity in treatment response and related health problems.
Article Abstract
Recent studies have found a relationship between obesity and chronic inflammation, confirmed by the association of high levels of tumor necrosis factor (TNF-_), interleukin six (IL-6,) and reactive C-protein with an increase in body mass index (BMI). In obese individuals, this inflammatory condition could contribute to the development or aggravation of psoriasis. Analogous phenomena have already been described in other inflammatory chronic diseases, such as rheumatoid arthritis and Crohn's disease. Epidemiological studies have identified a high prevalence of cardiovascular comorbidities, secondary to the metabolic alterations associated with psoriasis and obesity. A few aspects of this association remain unclear, such as the impact of obesity in the clinical forms of dermatoses, in the response to treatment, and its relationship with comorbidities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s0365-05962010000300009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Psoriasis is a chronic inflammatory skin disease often associated with obesity. Psoriasis therapies may be less effective in obese patients. The purpose of this expert consensus panel is to evaluate the relationship between obesity and efficacy of psoriasis therapies, thereby optimizing patient care.
View Article and Find Full Text PDFHospitalized hidradenitis suppurativa patients at a university clinic: a fifteen-year retrospective analysis of hospitalized patients with a focus on sex differences.
Acta Dermatovenerol Alp Pannonica Adriat
December 2024
Dermatology and Venereology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.
Introduction: Hidradenitis suppurativa (HS) is a chronic skin disease marked by recurrent abscesses, sinus tracts, and scarring, often accompanied by systemic symptoms. Diagnosed clinically, HS affects around 0.4% of people in western populations, but standardized treatment options are limited, leading to inconsistent outcomes.
View Article and Find Full Text PDFBiometrics and Biomarkers in Patients With Psoriasis.
Cureus
November 2024
Rheumatology, Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Davie, USA.
Psoriasis (PsO) is a chronic, systemic, and autoimmune dermatologic condition characterized by dry, scaly, and erythematous plaques on the skin. PsO can present in various forms, including guttate (small, round lesions commonly over the upper trunk and extremities that can be raised and scaly), inverse (smooth plaques of inflamed skin within skin folds of the groin, buttock, and breasts), pustular (white painful pustules within red inflamed blotches widespread over the body), and erythrodermic (red rash present over most of the body). Individuals with PsO can present differently, with unique symptoms and patterns on the skin.
View Article and Find Full Text PDFThe association between weight-adjusted-waist index and psoriasis: A cross-sectional study based on NHANES 2009 to 2014.
Medicine (Baltimore)
December 2024
Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
Weight-adjusted-waist index (WWI) is an anthropometric indicator of central obesity, which is calculated by dividing the waist circumference (WC) by the squared weight. The purpose of this study was to investigate the association between WWI and psoriasis in adults. Multivariate logistic regression and smoothing curve fitting were used to investigate the relationship between WWI and psoriasis based on data from the National Health and Nutrition Examination Survey (NHANES) 2009 to 2014.
View Article and Find Full Text PDFImpact of IL-17A Inhibitors on Serum Uric Acid Levels in Psoriatic Patients with Hyperuricemia: A Prospective Observational Study.
Psoriasis (Auckl)
November 2024
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, People's Republic of China.
Purpose: This prospective observational study investigated whether interleukin (IL)-17A inhibitors could reduce serum uric acid (SUA) levels in psoriatic patients with hyperuricemia. It also explored the risk factors for hyperuricemia in psoriatic patients and the effectiveness of IL-17A inhibitors for the skin lesions of psoriatic patients with hyperuricemia.
Methods: Patients aged ≥18 years with moderate to severe plaque psoriasis along with concomitant hyperuricemia (defined as an SUA level >416 μmol/L in men and >357 μmol/L in women) at baseline were treated with either secukinumab or ixekizumab.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!